HC Wainwright Reaffirms “Buy” Rating for Alimera Sciences (NASDAQ:ALIM)
HC Wainwright reiterated their buy rating on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a research report report published on Thursday, Benzinga reports. HC Wainwright currently has a $6.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Alimera Sciences’ Q3 2024 earnings at ($0.01) EPS, Q4 2024 earnings […]
More Stories
Canada’s Dollar-for-Dollar Tariff Response Exposes a Trade Relationship America Should Have Reexamined Decades Ago
By Stephen Zogopoulos, USNN World News Canada has now formally answered Washington’s latest tariffs with what it calls a “dollar-for-dollar,...
South Carolinians Go to Polls for Key Republican Senate Primary
By Joseph Lord CHARLESTON, S.C.—South Carolina voters will head to the polls today to make their pick in a runoff...
Iran Vows to Retaliate After US Rolls Out ‘Economic D-Day’ Sanctions
By Owen Evans Iran has promised to retaliate against the United States after Washington rolled out an “economic D-Day” sanctions...
ICE Arrests More Than 1,300 Illegal Immigrants in Virginia, Maryland in 2-Week Operation
By Aldra Fredly Immigration and Customs Enforcement (ICE) arrested more than 1,300 illegal immigrants during a two-week operation in Virginia...
Bessent Warns China, Others Not to Test US Resolve on Iran Sanctions
By Andrew Moran and Emel Akan Bessent, at an Aug. 24 news conference, unveiled the contours of the administration’s sweeping...
Gold Prices Surge to Highest Level in Over 3 Months
By Naveen Athrappully Gold prices are trading at their highest level in more than three months on Monday, amid continued...